PYC Therapeutics Says Safety Review Committee Approves Dose Escalation to Final Patient Group in Eye Disease Study; Shares Down 3%

MT Newswires11/05 09:21

PYC Therapeutics Moves Into Final Stage of Child Blindness Study

The Market Herald11/05 06:52

PYC Therapeutics Price Target Raised 9.1% to A$0.24/Share by Canaccord Genuity

Dow Jones10/23 08:32

PYC Therapeutics Ltd: 株主への年次報告書

ASX10/09 14:56

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

Yahoo Finance09/20 10:51

The Five-year Returns Have Been Stellar for PYC Therapeutics (ASX:PYC) Shareholders Despite Underlying Losses Increasing

Yahoo Finance08/31 04:17